|
Title: Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating
the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) versus Placebo in Patients with Acute Myocardial Infarction
Purpose: Myocardial infarction (heart attack) results from a blood clot forming in one of the coronary arteries. This blood clot blocks the flow
of blood into the heart resulting in injury and death to some of the heart muscle. Treatment involves a procedure called angioplasty which opens
up the blocked artery and restores blood flow to the heart muscle. However, if severe enough, some form of permanent (lasting) heart damage can
result. There may be a significant amount of heart tissue that has been injured that may not recover. In some cases, this injury may result in
enlargement of the heart and may lead to a condition called congestive heart failure.
Bone marrow contains special stem cells that may promote blood vessel growth, prevent cell death, and transform themselves into a
number of tissues including muscle. Recent studies in animals and humans have shown that these stem cells can improve heart muscle
function following a heart attack.
The purpose of this study is to determine if these cells taken from an individual’s bone marrow can be transplanted back into the
injured heart muscle of the individual and improve the heart’s function following a heart attack. Additionally, because this study
is transplanting these cells either 3 days or 7 days following a heart attack, it will help determine the best time for transplant
of these cells following such an event.
Enrollment: 120 individuals will be enrolled at the five clinical centers and will be followed for up to 24 months.
|